BASEL (dpa-AFX) - Novartis (NVS) announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 or siponimod in secondary progressive multiple sclerosis or SPMS, met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. The EXPAND study represents the largest randomized, controlled study in SPMS to date.
Top line results of the EXPAND study, including primary and key secondary endpoints, will be presented as a late breaking oral abstract at the 32(nd) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 17(th), in London, UK.
Novartis noted that it will complete full analyses of the data and evaluate next steps in consultation with health authorities.
Copyright RTT News/dpa-AFX
© 2016 AFX News
